Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors

NCT06596473 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT06596473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06596473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors
Lead sponsor
BeOne Medicines
Phase
Phase 1
Overall status
Recruiting
Start date
October 3, 2024
Completion date
December 31, 2027
Enrollment
310 (estimated)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors